Hope for DM1: Long-Term safety trial launches for experimental drug
NCT ID NCT07220603
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 34 times
Summary
This study looks at the long-term safety of an experimental drug called PGN-EDODM1 for people with myotonic dystrophy type 1 (DM1). It is for those who have already taken the drug in a previous study. About 48 adults will take part, and researchers will track any side effects over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CIUSSS du Saguenay-Lac-Saint-Jean
RECRUITINGSaguenay, Canada
Contact Email: •••••@•••••
-
Ottawa Hospital Research Institute
RECRUITINGOttawa, Ontario, Canada
Contact Email: •••••@•••••
-
University of Calgary
RECRUITINGCalgary, Alberta, T2N 4Z6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.